Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	actin binding	DST SYNE1 SPTAN1 PAWR ACTN2 DMD UTRN VCL MYBPC3	3.86e-05	479	69	9	GO:0003779
GeneOntologyCellularComponent	myofibril	DST SYNE1 SPTAN1 PDE4DIP ACTN2 DMD VCL AHNAK2 MYBPC3	2.77e-07	273	69	9	GO:0030016
GeneOntologyCellularComponent	contractile muscle fiber	DST SYNE1 SPTAN1 PDE4DIP ACTN2 DMD VCL AHNAK2 MYBPC3	4.60e-07	290	69	9	GO:0043292
GeneOntologyCellularComponent	sarcomere	DST SYNE1 SPTAN1 ACTN2 DMD VCL AHNAK2 MYBPC3	1.62e-06	249	69	8	GO:0030017
GeneOntologyCellularComponent	Z disc	DST SPTAN1 ACTN2 DMD VCL AHNAK2	1.06e-05	151	69	6	GO:0030018
GeneOntologyCellularComponent	I band	DST SPTAN1 ACTN2 DMD VCL AHNAK2	1.82e-05	166	69	6	GO:0031674
GeneOntologyCellularComponent	costamere	DMD VCL AHNAK2	5.07e-05	22	69	3	GO:0043034
GeneOntologyCellularComponent	sarcolemma	DST DMD UTRN VCL AHNAK2	4.13e-04	190	69	5	GO:0042383
GeneOntologyCellularComponent	supramolecular fiber	CFAP107 DST SYNE1 SPTAN1 PDE4DIP KIF14 PAWR ACTN2 DMD VCL AHNAK2 MYBPC3	4.36e-04	1179	69	12	GO:0099512
GeneOntologyCellularComponent	supramolecular polymer	CFAP107 DST SYNE1 SPTAN1 PDE4DIP KIF14 PAWR ACTN2 DMD VCL AHNAK2 MYBPC3	4.63e-04	1187	69	12	GO:0099081
GeneOntologyCellularComponent	fascia adherens	SPTAN1 VCL	8.18e-04	13	69	2	GO:0005916
GeneOntologyCellularComponent	intercalated disc	DST SPTAN1 VCL	1.48e-03	68	69	3	GO:0014704
HumanPheno	Myofiber disarray	ACTN2 VCL MYBPC3	3.17e-05	12	28	3	HP:0031318
HumanPheno	Dilated cardiomyopathy	ALMS1 SYNE1 ACTN2 DMD ADA2 VCL MYBPC3	4.45e-05	184	28	7	HP:0001644
HumanPheno	Thromboembolic stroke	ACTN2 DMD ADA2 VCL MYBPC3	4.56e-05	75	28	5	HP:0001727
HumanPheno	Abnormal adipose tissue morphology	ERCC4 ALMS1 SYNE1 ACTN2 DMD ADA2 VCL MYBPC3	5.41e-05	261	28	8	HP:0009124
Domain	Spectrin	DST SYNE1 SPTAN1 ACTN2 DMD UTRN	1.79e-10	23	68	6	PF00435
Domain	Spectrin_repeat	DST SYNE1 SPTAN1 ACTN2 DMD UTRN	8.27e-10	29	68	6	IPR002017
Domain	Spectrin/alpha-actinin	DST SYNE1 SPTAN1 ACTN2 DMD UTRN	1.56e-09	32	68	6	IPR018159
Domain	SPEC	DST SYNE1 SPTAN1 ACTN2 DMD UTRN	1.56e-09	32	68	6	SM00150
Domain	Actinin_actin-bd_CS	DST SYNE1 ACTN2 DMD UTRN	1.76e-08	23	68	5	IPR001589
Domain	ACTININ_2	DST SYNE1 ACTN2 DMD UTRN	1.76e-08	23	68	5	PS00020
Domain	ACTININ_1	DST SYNE1 ACTN2 DMD UTRN	1.76e-08	23	68	5	PS00019
Domain	CH	DST SYNE1 ACTN2 DMD UTRN	3.84e-06	65	68	5	SM00033
Domain	CH	DST SYNE1 ACTN2 DMD UTRN	5.55e-06	70	68	5	PF00307
Domain	-	DST SYNE1 ACTN2 DMD UTRN	5.96e-06	71	68	5	1.10.418.10
Domain	CH	DST SYNE1 ACTN2 DMD UTRN	6.83e-06	73	68	5	PS50021
Domain	CH-domain	DST SYNE1 ACTN2 DMD UTRN	7.81e-06	75	68	5	IPR001715
Domain	Dystrophin	DMD UTRN	1.31e-05	2	68	2	IPR016344
Domain	EF-hand_Ca_insen	SPTAN1 ACTN2	1.94e-04	6	68	2	IPR014837
Domain	EF-hand_dom_typ1	DMD UTRN	1.94e-04	6	68	2	IPR015153
Domain	EF-hand_dom_typ2	DMD UTRN	1.94e-04	6	68	2	IPR015154
Domain	EF-hand_2	DMD UTRN	1.94e-04	6	68	2	PF09068
Domain	EF-hand_3	DMD UTRN	1.94e-04	6	68	2	PF09069
Domain	EFhand_Ca_insen	SPTAN1 ACTN2	1.94e-04	6	68	2	PF08726
Domain	Serpin_CS	SERPINI2 SERPINB3 SERPINB4	2.12e-04	32	68	3	IPR023795
Domain	Serpin_dom	SERPINI2 SERPINB3 SERPINB4	3.02e-04	36	68	3	IPR023796
Domain	SERPIN	SERPINI2 SERPINB3 SERPINB4	3.28e-04	37	68	3	SM00093
Domain	SERPIN	SERPINI2 SERPINB3 SERPINB4	3.28e-04	37	68	3	PS00284
Domain	Serpin	SERPINI2 SERPINB3 SERPINB4	3.55e-04	38	68	3	PF00079
Domain	Serpin_fam	SERPINI2 SERPINB3 SERPINB4	3.84e-04	39	68	3	IPR000215
Domain	Elongated_TPR_rpt_dom	SPAG1 FKBP5	7.03e-04	11	68	2	IPR023114
Domain	NBPF_dom	PDE4DIP NBPF7P	7.03e-04	11	68	2	IPR010630
Domain	NBPF	PDE4DIP NBPF7P	7.03e-04	11	68	2	PS51316
Domain	DUF1220	PDE4DIP NBPF7P	7.03e-04	11	68	2	PF06758
Domain	ZZ	DMD UTRN	1.92e-03	18	68	2	PF00569
Domain	ZF_ZZ_2	DMD UTRN	1.92e-03	18	68	2	PS50135
Domain	ZF_ZZ_1	DMD UTRN	1.92e-03	18	68	2	PS01357
Domain	Znf_ZZ	DMD UTRN	2.15e-03	19	68	2	IPR000433
Domain	ZnF_ZZ	DMD UTRN	2.15e-03	19	68	2	SM00291
Domain	-	DST SPTAN1 ACTN2 DMD UTRN	2.61e-03	261	68	5	1.10.238.10
Domain	fn3	IGSF22 CNTN5 PHYHIPL MYBPC3	2.89e-03	162	68	4	PF00041
Domain	EF-hand-dom_pair	DST SPTAN1 ACTN2 DMD UTRN	3.92e-03	287	68	5	IPR011992
Domain	SAM	DGKH SAMD3 ARAP1	4.06e-03	88	68	3	SM00454
Domain	FN3	IGSF22 CNTN5 PHYHIPL MYBPC3	4.63e-03	185	68	4	SM00060
Domain	SAM_DOMAIN	DGKH SAMD3 ARAP1	5.03e-03	95	68	3	PS50105
Domain	SAM	DGKH SAMD3 ARAP1	5.33e-03	97	68	3	IPR001660
Domain	FN3	IGSF22 CNTN5 PHYHIPL MYBPC3	5.99e-03	199	68	4	PS50853
Domain	-	DGKH SAMD3 ARAP1	6.82e-03	106	68	3	1.10.150.50
Domain	FN3_dom	IGSF22 CNTN5 PHYHIPL MYBPC3	7.10e-03	209	68	4	IPR003961
Pubmed	HENA, heterogeneous network-based data set for Alzheimer's disease.	DST ALMS1 SYNE1 SPTAN1 PDE4DIP CEP135 ACTN2 DMD	1.41e-10	120	71	8	31413325
Pubmed	Disrupted in Schizophrenia 1 Interactome: evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia.	NCOR2 DST SYNE1 SPTAN1 PDE4DIP DMD UTRN	2.66e-08	151	71	7	17043677
Pubmed	Role of dystrophins and utrophins in platelet adhesion process.	DMD UTRN VCL	8.13e-08	5	71	3	16803572
Pubmed	Kinetics of cardiac muscle contraction and relaxation are linked and determined by properties of the cardiac sarcomere.	DMD UTRN MYBPC3	8.13e-08	5	71	3	20656885
Pubmed	A comprehensive proteomics-based interaction screen that links DYRK1A to RNF169 and to the DNA damage response.	NCOR2 SPTAN1 KIF14 PAWR UTRN AHNAK2	1.61e-07	118	71	6	30979931
Pubmed	Small mammalian animal models of heart disease.	DMD UTRN MYBPC3	1.62e-07	6	71	3	27679742
Pubmed	Agrin has a pathological role in the progression of oral cancer.	NCOR2 SERPINB3 SYNE1 SPTAN1 KIF14 ACTN2 DMD	1.65e-07	197	71	7	29872149
Pubmed	The protein network surrounding the human telomere repeat binding factors TRF1, TRF2, and POT1.	DST SYNE1 SPTAN1 DMD YY1 UTRN LARP7	1.65e-07	197	71	7	20811636
Pubmed	HSF1 phosphorylation establishes an active chromatin state via the TRRAP-TIP60 complex and promotes tumorigenesis.	ABCC1 NCOR2 SERPINB3 SYNE1 SPTAN1 HLTF KIF14 DMD ECE1 RNF17 RSL24D1	3.63e-07	754	71	11	35906200
Pubmed	Dilated Cardiomyopathy Overview	ACTN2 DMD VCL MYBPC3	5.49e-07	32	71	4	20301486
Pubmed	A human skeletal muscle interactome centered on proteins involved in muscular dystrophies: LGMD interactome.	DST ALMS1 PPP1R3B SYNE1 PDE4DIP ACTN2 UTRN TRIM38 VCL	7.85e-07	497	71	9	23414517
Pubmed	Relationship between sex, shape, and substrate in hypertrophic cardiomyopathy.	ACTN2 VCL MYBPC3	2.30e-06	13	71	3	18513529
Pubmed	Kelch Domain of Gigaxonin Interacts with Intermediate Filament Proteins Affected in Giant Axonal Neuropathy.	PRPF31 DST ALMS1 SYNE1 SPTAN1 DMD	2.39e-06	187	71	6	26460568
Pubmed	Functional proteomics mapping of a human signaling pathway.	NCOR2 DST PPP1R3B PDE4DIP CFDP1 CEP135 GMEB1 UTRN VCL	3.25e-06	591	71	9	15231748
Pubmed	The amplified mouse squamous cell carcinoma antigen gene locus contains a serpin (Serpinb3b) that inhibits both papain-like cysteine and trypsin-like serine proteinases.	SERPINB3 SERPINB4	4.11e-06	2	71	2	15203214
Pubmed	Increased Th1 immune response in SERPINB3 transgenic mice during acute liver failure.	SERPINB3 SERPINB4	4.11e-06	2	71	2	23354406
Pubmed	Serpin B4 isoform overexpression is associated with aberrant epithelial proliferation and lung cancer in idiopathic pulmonary fibrosis.	SERPINB3 SERPINB4	4.11e-06	2	71	2	22406480
Pubmed	Decreased myocardial nNOS, increased iNOS and abnormal ECGs in mouse models of Duchenne muscular dystrophy.	DMD UTRN	4.11e-06	2	71	2	10525423
Pubmed	Distribution of dystrophin- and utrophin-associated protein complexes during activation of human neutrophils.	DMD UTRN	4.11e-06	2	71	2	20434517
Pubmed	Plasma lipidomic analysis shows a disease progression signature in mdx mice.	DMD UTRN	4.11e-06	2	71	2	34155298
Pubmed	In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice.	DMD UTRN	4.11e-06	2	71	2	28790199
Pubmed	Dystrophic changes in extraocular muscles after gamma irradiation in mdx:utrophin(+/-) mice.	DMD UTRN	4.11e-06	2	71	2	24466085
Pubmed	Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy.	SERPINB3 SERPINB4	4.11e-06	2	71	2	27668655
Pubmed	The Angiotensin Converting Enzyme Inhibitor Lisinopril Improves Muscle Histopathology but not Contractile Function in a Mouse Model of Duchenne Muscular Dystrophy.	DMD UTRN	4.11e-06	2	71	2	27110493
Pubmed	Rapid depletion of muscle progenitor cells in dystrophic mdx/utrophin-/- mice.	DMD UTRN	4.11e-06	2	71	2	24781208
Pubmed	Isolation and characterization of a genomic clone from the murine utrophin locus.	DMD UTRN	4.11e-06	2	71	2	8268660
Pubmed	Metabolic dysfunction and altered mitochondrial dynamics in the utrophin-dystrophin deficient mouse model of duchenne muscular dystrophy.	DMD UTRN	4.11e-06	2	71	2	25859846
Pubmed	G-utrophin, the autosomal homologue of dystrophin Dp116, is expressed in sensory ganglia and brain.	DMD UTRN	4.11e-06	2	71	2	7731967
Pubmed	Characterization of neuromuscular synapse function abnormalities in multiple Duchenne muscular dystrophy mouse models.	DMD UTRN	4.11e-06	2	71	2	27037492
Pubmed	Role of dystrophin and utrophin for assembly and function of the dystrophin glycoprotein complex in non-muscle tissue.	DMD UTRN	4.11e-06	2	71	2	16710609
Pubmed	Improvement in survival and muscle function in an mdx/utrn(-/-) double mutant mouse using a human retinal dystrophin transgene.	DMD UTRN	4.11e-06	2	71	2	16487708
Pubmed	Nonclinical Exon Skipping Studies with 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides in mdx and mdx-utrn-/- Mice Inspired by Clinical Trial Results.	DMD UTRN	4.11e-06	2	71	2	30672725
Pubmed	Voltage-gated ion channel dysfunction precedes cardiomyopathy development in the dystrophic heart.	DMD UTRN	4.11e-06	2	71	2	21677768
Pubmed	Talin, vinculin and DRP (utrophin) concentrations are increased at mdx myotendinous junctions following onset of necrosis.	DMD UTRN	4.11e-06	2	71	2	7962191
Pubmed	Consequences of the combined deficiency in dystrophin and utrophin on the mechanical properties and myosin composition of some limb and respiratory muscles of the mouse.	DMD UTRN	4.11e-06	2	71	2	9713852
Pubmed	Skeletal muscle fibrosis in the mdx/utrn+/- mouse validates its suitability as a murine model of Duchenne muscular dystrophy.	DMD UTRN	4.11e-06	2	71	2	25607927
Pubmed	Does utrophin expression in muscles of mdx mice during postnatal development functionally compensate for dystrophin deficiency?	DMD UTRN	4.11e-06	2	71	2	8021701
Pubmed	Correlation of Utrophin Levels with the Dystrophin Protein Complex and Muscle Fibre Regeneration in Duchenne and Becker Muscular Dystrophy Muscle Biopsies.	DMD UTRN	4.11e-06	2	71	2	26974331
Pubmed	Developmental studies of dystrophin-positive fibers in mdx, and DRP localization.	DMD UTRN	4.11e-06	2	71	2	8433092
Pubmed	Second-generation compound for the modulation of utrophin in the therapy of DMD.	DMD UTRN	4.11e-06	2	71	2	25935002
Pubmed	Utrophin deficiency worsens cardiac contractile dysfunction present in dystrophin-deficient mdx mice.	DMD UTRN	4.11e-06	2	71	2	16024571
Pubmed	Androgen receptor agonists increase lean mass, improve cardiopulmonary functions and extend survival in preclinical models of Duchenne muscular dystrophy.	DMD UTRN	4.11e-06	2	71	2	28453658
Pubmed	A quantitative study of bioenergetics in skeletal muscle lacking utrophin and dystrophin.	DMD UTRN	4.11e-06	2	71	2	11801396
Pubmed	Apo-dystrophin-1 and apo-dystrophin-2, products of the Duchenne muscular dystrophy locus: expression during mouse embryogenesis and in cultured cell lines.	DMD UTRN	4.11e-06	2	71	2	7987307
Pubmed	Utility of dystrophin and utrophin staining in childhood muscular dystrophy.	DMD UTRN	4.11e-06	2	71	2	16295426
Pubmed	Comparative analysis of the human dystrophin and utrophin gene structures.	DMD UTRN	4.11e-06	2	71	2	11861579
Pubmed	Distinct mechanical properties in homologous spectrin-like repeats of utrophin.	DMD UTRN	4.11e-06	2	71	2	30914715
Pubmed	Dystrophin is a microtubule-associated protein.	DMD UTRN	4.11e-06	2	71	2	19651889
Pubmed	Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice.	DMD UTRN	4.11e-06	2	71	2	9590295
Pubmed	Comparison of skeletal muscle pathology and motor function of dystrophin and utrophin deficient mouse strains.	DMD UTRN	4.11e-06	2	71	2	22284942
Pubmed	Utrophin haploinsufficiency does not worsen the functional performance, resistance to eccentric contractions and force production of dystrophic mice.	DMD UTRN	4.11e-06	2	71	2	29879154
Pubmed	Haploinsufficiency of utrophin gene worsens skeletal muscle inflammation and fibrosis in mdx mice.	DMD UTRN	4.11e-06	2	71	2	17889902
Pubmed	Identification of Dp71 isoforms in the platelet membrane cytoskeleton. Potential role in thrombin-mediated platelet adhesion.	DMD UTRN	4.11e-06	2	71	2	12370193
Pubmed	Longitudinal metabolomic analysis of plasma enables modeling disease progression in Duchenne muscular dystrophy mouse models.	DMD UTRN	4.11e-06	2	71	2	32025735
Pubmed	Lifelong quercetin enrichment and cardioprotection in Mdx/Utrn+/- mice.	DMD UTRN	4.11e-06	2	71	2	27836895
Pubmed	BGP-15 Improves Aspects of the Dystrophic Pathology in mdx and dko Mice with Differing Efficacies in Heart and Skeletal Muscle.	DMD UTRN	4.11e-06	2	71	2	27750047
Pubmed	Cardiac myosin binding protein-C plays no regulatory role in skeletal muscle structure and function.	DMD MYBPC3	4.11e-06	2	71	2	23936073
Pubmed	Prevention of dystrophin-deficient cardiomyopathy in twenty-one-month-old carrier mice by mosaic dystrophin expression or complementary dystrophin/utrophin expression.	DMD UTRN	4.11e-06	2	71	2	17967782
Pubmed	Diaphragm rescue alone prevents heart dysfunction in dystrophic mice.	DMD UTRN	4.11e-06	2	71	2	21062902
Pubmed	Matricellular Protein CCN5 Gene Transfer Ameliorates Cardiac and Skeletal Dysfunction in mdx/utrn (±) Haploinsufficient Mice by Reducing Fibrosis and Upregulating Utrophin Expression.	DMD UTRN	4.11e-06	2	71	2	35557546
Pubmed	Spectrin-like repeats from dystrophin and alpha-actinin-2 are not functionally interchangeable.	ACTN2 DMD	4.11e-06	2	71	2	12140183
Pubmed	Characterization of the Ang/Tie2 Signaling Pathway in the Diaphragm Muscle of DMD Mice.	DMD UTRN	4.11e-06	2	71	2	37626761
Pubmed	Molecular heterogeneity of the dystrophin-associated protein complex in the mouse kidney nephron: differential alterations in the absence of utrophin and dystrophin.	DMD UTRN	4.11e-06	2	71	2	15565469
Pubmed	[No Effect of the p.Arg230His Variant Of The VCL Protein on the Course of the Hypertrophic Cardiomyopathy In Russian Family Carrying The p.Gln1233Ter Pathogenic Variant In The MYBPC3 Gene].	VCL MYBPC3	4.11e-06	2	71	2	37061858
Pubmed	The N- and C-Terminal Domains Differentially Contribute to the Structure and Function of Dystrophin and Utrophin Tandem Calponin-Homology Domains.	DMD UTRN	4.11e-06	2	71	2	26516677
Pubmed	Assessment of cardiac function in three mouse dystrophinopathies by magnetic resonance imaging.	DMD UTRN	4.11e-06	2	71	2	22209498
Pubmed	Characterization of novel squamous cell carcinoma antigen-related molecules in mice.	SERPINB3 SERPINB4	4.11e-06	2	71	2	15504361
Pubmed	A Protocol for Simultaneous In Vivo Imaging of Cardiac and Neuroinflammation in Dystrophin-Deficient MDX Mice Using [18F]FEPPA PET.	DMD UTRN	4.11e-06	2	71	2	37108685
Pubmed	Prevention of the dystrophic phenotype in dystrophin/utrophin-deficient muscle following adenovirus-mediated transfer of a utrophin minigene.	DMD UTRN	4.11e-06	2	71	2	10694796
Pubmed	Dystrophin and dystrophin-related protein in the central nervous system of normal controls and Duchenne muscular dystrophy.	DMD UTRN	4.11e-06	2	71	2	8171962
Pubmed	Similar efficacy from specific and non-specific mineralocorticoid receptor antagonist treatment of muscular dystrophy mice.	DMD UTRN	4.11e-06	2	71	2	27822449
Pubmed	Micro-dystrophin gene therapy prevents heart failure in an improved Duchenne muscular dystrophy cardiomyopathy mouse model.	DMD UTRN	4.11e-06	2	71	2	33651713
Pubmed	SCCA2-like serpins mediate genetic predisposition to skin tumors.	SERPINB3 SERPINB4	4.11e-06	2	71	2	12702576
Pubmed	Thermodynamic stability, unfolding kinetics, and aggregation of the N-terminal actin-binding domains of utrophin and dystrophin.	DMD UTRN	4.11e-06	2	71	2	22275054
Pubmed	NAD+ repletion improves muscle function in muscular dystrophy and counters global PARylation.	DMD UTRN	4.11e-06	2	71	2	27798264
Pubmed	Glycine administration attenuates progression of dystrophic pathology in prednisolone-treated dystrophin/utrophin null mice.	DMD UTRN	4.11e-06	2	71	2	31506484
Pubmed	Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy.	DMD UTRN	4.11e-06	2	71	2	9288752
Pubmed	Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy.	DMD UTRN	4.11e-06	2	71	2	9288751
Pubmed	Enhanced currents through L-type calcium channels in cardiomyocytes disturb the electrophysiology of the dystrophic heart.	DMD UTRN	4.11e-06	2	71	2	24337461
Pubmed	Combined gene therapy via VEGF and mini-dystrophin synergistically improves pathologies in temporalis muscle of dystrophin/utrophin double knockout mice.	DMD UTRN	4.11e-06	2	71	2	33987645
Pubmed	Activation of calcineurin and stress activated protein kinase/p38-mitogen activated protein kinase in hearts of utrophin-dystrophin knockout mice.	DMD UTRN	4.11e-06	2	71	2	11297940
Pubmed	Utrophin up-regulation by artificial transcription factors induces muscle rescue and impacts the neuromuscular junction in mdx mice.	DMD UTRN	4.11e-06	2	71	2	29408646
Pubmed	Serpinb3 is overexpressed in the liver in presence of iron overload.	SERPINB3 SERPINB4	4.11e-06	2	71	2	28935635
Pubmed	Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping.	DMD UTRN	4.11e-06	2	71	2	22388933
Pubmed	Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers.	DMD UTRN	4.11e-06	2	71	2	25642938
Pubmed	Activation of non-myogenic mesenchymal stem cells during the disease progression in dystrophic dystrophin/utrophin knockout mice.	DMD UTRN	4.11e-06	2	71	2	25859011
Pubmed	Lysoptosis is an evolutionarily conserved cell death pathway moderated by intracellular serpins.	SERPINB3 SERPINB4	4.11e-06	2	71	2	35022507
Pubmed	Satellite cells and utrophin are not directly correlated with the degree of skeletal muscle damage in mdx mice.	DMD UTRN	4.11e-06	2	71	2	15703201
Pubmed	Microtubule binding distinguishes dystrophin from utrophin.	DMD UTRN	4.11e-06	2	71	2	24706788
Pubmed	Utrophin suppresses low frequency oscillations and coupled gating of mechanosensitive ion channels in dystrophic skeletal muscle.	DMD UTRN	4.11e-06	2	71	2	25941878
Pubmed	Duchenne muscular dystrophy and the neuromuscular junction: the utrophin link.	DMD UTRN	4.11e-06	2	71	2	9297964
Pubmed	Overexpression of SERPIN B3 promotes epithelial proliferation and lung fibrosis in mice.	SERPINB3 SERPINB4	4.11e-06	2	71	2	21403642
Pubmed	Dystrophin and utrophin do not play crucial roles in nonmuscle tissues in mice.	DMD UTRN	4.11e-06	2	71	2	10204788
Pubmed	SERCA1 overexpression minimizes skeletal muscle damage in dystrophic mouse models.	DMD UTRN	4.11e-06	2	71	2	25652448
Pubmed	Utrophin Compensates dystrophin Loss during Mouse Spermatogenesis.	DMD UTRN	4.11e-06	2	71	2	28785010
Pubmed	The role of proteases in excitation-contraction coupling failure in muscular dystrophy.	DMD UTRN	4.11e-06	2	71	2	25298424
Pubmed	Restoration of all dystrophin protein interactions by functional domains in trans does not rescue dystrophy.	DMD UTRN	4.11e-06	2	71	2	16307000
Pubmed	Expression of the dystrophin isoform Dp116 preserves functional muscle mass and extends lifespan without preventing dystrophy in severely dystrophic mice.	DMD UTRN	4.11e-06	2	71	2	21949353
Pubmed	Dystrophin and utrophin "double knockout" dystrophic mice exhibit a spectrum of degenerative musculoskeletal abnormalities.	DMD UTRN	4.11e-06	2	71	2	23097179
Pubmed	rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice.	DMD UTRN	4.11e-06	2	71	2	16819550
Interaction	CEP63 interactions	NCOR2 CWF19L2 DST ALMS1 SYNE1 SPTAN1 CEP135 KIF14	1.55e-07	179	68	8	int:CEP63
Interaction	DISC1 interactions	CWF19L2 DST ALMS1 SYNE1 SPTAN1 PDE4DIP ACTN2 DMD UTRN LARP7	1.66e-06	429	68	10	int:DISC1
Interaction	PGM5 interactions	DMD UTRN VCL	5.95e-06	11	68	3	int:PGM5
Interaction	COIL interactions	PRPF31 CWF19L2 DDX52 CFDP1 HLTF KIF14 UTP20 ACTN2 YY1 LARP7	1.53e-05	552	68	10	int:COIL
Interaction	PCNT interactions	DST ALMS1 SYNE1 SPTAN1 CEP135 KIF14 UTRN	1.67e-05	241	68	7	int:PCNT
Interaction	RHOV interactions	ABCC1 DST DDX52 SPTAN1 HLTF UTP20 SLC12A7	1.76e-05	243	68	7	int:RHOV
Interaction	ZFPL1 interactions	ABCC1 DST SERPINB3 SERPINB4 SPTAN1 SSMEM1 SLC12A7 UTRN AHNAK2	1.89e-05	448	68	9	int:ZFPL1
Interaction	AGRN interactions	NCOR2 SERPINB3 SYNE1 SPTAN1 KIF14 ACTN2 DMD	3.22e-05	267	68	7	int:AGRN
Interaction	PDE4DIP interactions	PRPF31 CWF19L2 SERPINB3 SERPINB4 PDE4DIP KIF14	4.24e-05	189	68	6	int:PDE4DIP
Interaction	CCNT2 interactions	CWF19L2 CYP21A2 YY1 LARP7	5.71e-05	62	68	4	int:CCNT2
Interaction	TRRAP interactions	ABCC1 NCOR2 SERPINB3 SYNE1 SPTAN1 KIF14 DMD ECE1 RNF17 YY1 RSL24D1	6.24e-05	790	68	11	int:TRRAP
Interaction	ACTC1 interactions	PRPF31 DST SYNE1 SPTAN1 CFDP1 KIF14 DMD UTRN LARP7 VCL	1.05e-04	694	68	10	int:ACTC1
Cytoband	18q21.3	SERPINB3 SERPINB4	1.29e-04	11	71	2	18q21.3
GeneFamily	Serpin peptidase inhibitors	SERPINI2 SERPINB3 SERPINB4	1.13e-04	37	46	3	739
GeneFamily	Fibronectin type III domain containing	IGSF22 CNTN5 PHYHIPL MYBPC3	7.22e-04	160	46	4	555
GeneFamily	Zinc fingers ZZ-type\|Lysine acetyltransferases	DMD UTRN	9.44e-04	18	46	2	91
GeneFamily	Sterile alpha motif domain containing	DGKH SAMD3 ARAP1	1.45e-03	88	46	3	760
Coexpression	DACOSTA_UV_RESPONSE_VIA_ERCC3_DN	PIKFYVE ABCC1 NCOR2 DST CEP135 HLTF KIF14 UTP20 PAWR DMD YY1 VCL	2.97e-06	856	71	12	M4500
Coexpression	LAKE_ADULT_KIDNEY_C27_VASCULAR_SMOOTH_MUSCLE_CELLS_AND_PERICYTES	DST DGKH PAWR DMD UTRN VCL	4.05e-06	155	71	6	M39246
Coexpression	AIZARANI_LIVER_C30_HEPATOCYTES_4	NUGGC DST PPP1R3B ZNF283 PDE4DIP GMEB1 DGKH FKBP5	2.75e-05	446	71	8	M39129
CoexpressionAtlas	FacebaseRNAseq_e8.5_Hind Brain Neural Epithelium_top-relative-expression-ranked_2500_k-means-cluster#3	ABCC1 CWF19L2 ALMS1 DDX52 SPTAN1 CEP135 KIF14 SMIM15 PHYHIPL LARP7	8.08e-06	532	69	10	Facebase_RNAseq_e8.5_Hind Brain Neural Epithelium_2500_K3
ToppCell	mild-low-quality_cells\|mild / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	CWF19L2 SYNE1 ZNF507 DGKH SFI1 SAMD3 UTRN	2.91e-08	197	71	7	e4331969bd911d1ebb5453f40a7057297b5389b4
ToppCell	LPS_anti-TNF-Endothelial-Endothelial-Gen_Cap\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	PITPNM2 DST KIAA0825 SPTAN1 DGKH ECE1 UTRN	3.23e-08	200	71	7	a2b9d1cd291d17abddc3ee2e242121412c864b8b
ToppCell	LV-15._Ventricular_Cardiomyocyte_III\|LV / Chamber and Cluster_Paper	DST PDE4DIP ACTN2 DMD VCL MYBPC3	4.95e-07	184	71	6	ab7a1620c14a9d9b6be1b47c559931e345e9eef8
ToppCell	Control-Epithelial-Basal\|Epithelial / Disease state, Lineage and Cell class	ABCC1 DST SERPINB3 SERPINB4 DGKH ECE1	5.11e-07	185	71	6	d5d6d13e2f20b54ca55645b9a757b8599f4fd897
ToppCell	LPS_IL1RA-Endothelial-Endothelial-Gen_Cap\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	PITPNM2 DST SPTAN1 DGKH ECE1 UTRN	8.06e-07	200	71	6	dccec522ab0d7fff62ad6273b02aa9022dbbb8eb
ToppCell	3'-Airway_Nasal-Epithelial-Airway_epithelium-respiratory_basal_cell-Suprabasal-Suprabasal_L.0.0.1.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	NRXN1 SERPINB3 SERPINB4 ZNF507 RNF17	5.58e-06	159	71	5	22427ad4ad2e797e4664e7a7b0514094f22a18b2
ToppCell	COPD-Epithelial-Basal\|Epithelial / Disease state, Lineage and Cell class	ABCC1 SERPINB3 SERPINB4 DGKH ECE1	9.66e-06	178	71	5	441d1dba720141891b11f404744c59834d80e6c5
ToppCell	COVID-19_Mild-gd_T\|COVID-19_Mild / Disease condition and Cell class	NUGGC SYNE1 SAMD3 UTRN VCL	1.10e-05	183	71	5	f593a89b0aa8fffdfa403769916facfd30358521
ToppCell	LV-15._Ventricular_Cardiomyocyte_III\|World / Chamber and Cluster_Paper	PDE4DIP ACTN2 DMD VCL MYBPC3	1.16e-05	185	71	5	6baccb26f999145e51b91d94315bf8d4655bef31
ToppCell	MS-CD8-CD4_Treg\|MS / Condition, Cell_class and T cell subcluster	ABCC1 SPAG1 GMEB1 UTP20 SAMD3	1.26e-05	188	71	5	2f0e2c7d79ee2d69a5d908c0247dc950c056c30a
ToppCell	RV-06._Ventricular_Cardiomyocyte_II\|RV / Chamber and Cluster_Paper	DST PDE4DIP ACTN2 DMD MYBPC3	1.32e-05	190	71	5	fe8e78922c8ae928ef9a80bffd67868d5a87a091
ToppCell	LV-06._Ventricular_Cardiomyocyte_II\|LV / Chamber and Cluster_Paper	DST PDE4DIP ACTN2 DMD MYBPC3	1.36e-05	191	71	5	25f3eb34f4e70761e81e84c8a5829f216108cbc6
ToppCell	Control-Lymphoid_T/NK-NK_CD56bright\|Control / Disease group, lineage and cell class	SPAG1 SYNE1 PAWR SAMD3 UTRN	1.36e-05	191	71	5	e842f29bc03ed6734b2a7b975e7830a498f2743c
ToppCell	COVID-19-Heart-CM_+_EC_+_Pericyte\|Heart / Disease (COVID-19 only), tissue and cell type	PDE4DIP ACTN2 DMD VCL MYBPC3	1.43e-05	193	71	5	dd5378a1ef8eb0eda9a3aae62f3c2f3a1402bda0
ToppCell	LPS-IL1RA-Endothelial-Endothelial-Gen_Cap\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PITPNM2 DST KIAA0825 DGKH ECE1	1.46e-05	194	71	5	0b9cd96fa0b616da7cc90e92ff71157e9bba518f
ToppCell	PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	ABCC1 HTR7 DGKH SFI1 FKBP5	1.46e-05	194	71	5	a44be2f021cfdd0fcdc698c3f04d66db7a1aa6c2
ToppCell	COVID-19-Heart-CM_2\|Heart / Disease (COVID-19 only), tissue and cell type	DST PDE4DIP ACTN2 DMD MYBPC3	1.50e-05	195	71	5	75fc81bddb246dca3b437fb60827b1d4fe416405
ToppCell	Basal_cells-Myositis-ILD_01\|World / lung cells shred on cell class, cell subclass, sample id	DST SERPINB3 SERPINB4 DGKH ECE1	1.54e-05	196	71	5	3b66f3a79b3f2ebacb4ad646f179e505ab38d6f0
ToppCell	Basal_cells\|World / lung cells shred on cell class, cell subclass, sample id	DST SERPINB3 SERPINB4 DGKH ECE1	1.58e-05	197	71	5	24360b660000bdfb999d58fbf4e29585a97e1785
ToppCell	T_cells-Treg_cells\|World / Immune cells in Kidney/Urine in Lupus Nephritis	PCNX2 SPTAN1 PDE4DIP DGKH SFI1	1.58e-05	197	71	5	de5448fcdf4e433fc167496413abe5d0c8a5c6d8
ToppCell	Epithelial_cells-Basal_cells\|Epithelial_cells / lung cells shred on cell class, cell subclass, sample id	DST SERPINB3 SERPINB4 DGKH ECE1	1.61e-05	198	71	5	4235005c49fc2b29ad3a0ee6b608f0109d04f775
ToppCell	mild-low-quality_cells\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	CWF19L2 SYNE1 SFI1 SAMD3 UTRN	1.65e-05	199	71	5	f0b0097df0026496470a80d8cc9375ffd8389b00
ToppCell	mild-NK_CD56bright\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	SPAG1 DST PAWR SAMD3 UTRN	1.69e-05	200	71	5	a195bc6784346f706d4cd5b740adac1d950ce88a
ToppCell	LV-03._Atrial_Cardiomyocyte\|LV / Chamber and Cluster_Paper	PDE4DIP ACTN2 DMD MYBPC3	4.07e-05	120	71	4	3b77bd0e3630cdd45001cecf5e47660a90ebc92e
ToppCell	RV-03._Atrial_Cardiomyocyte\|World / Chamber and Cluster_Paper	PDE4DIP ACTN2 DMD MYBPC3	4.34e-05	122	71	4	1cb1dd03b2aaedbe04f3ed907568c3b7f54767b3
ToppCell	LV-03._Atrial_Cardiomyocyte\|World / Chamber and Cluster_Paper	PDE4DIP ACTN2 DMD MYBPC3	5.57e-05	130	71	4	a3e12984fb61311e49cc76c59f74f4dffc48faa1
ToppCell	RA-06._Ventricular_Cardiomyocyte_II\|World / Chamber and Cluster_Paper	SERPINI2 PNLDC1 DMD MYBPC3	6.45e-05	135	71	4	6121b1d30d05b7d476661b932f51191da09dfeeb
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling-Cycling_Proximal_Tubule_Epithelial_Cell_low-phase\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	CFAP107 KIAA0825 KIF14 MYBPC3	9.45e-05	149	71	4	a6406c4c9404271a2f4c615c6cd3265b2d759b12
ToppCell	Club_cells-Cryobiopsy_01\|World / lung cells shred on cell class, cell subclass, sample id	NRXN1 SERPINB3 SERPINB4 ECE1	9.45e-05	149	71	4	81c813588bb5efb7b31141a75d387210dcb76094
ToppCell	RV-13._Vascular_Smooth_Muscle\|World / Chamber and Cluster_Paper	DGKH PAWR DMD UTRN	1.24e-04	160	71	4	29c9b4770d0e73d59cffc7937b179484c76b6dcc
ToppCell	RV-13._Vascular_Smooth_Muscle\|RV / Chamber and Cluster_Paper	DGKH PAWR DMD UTRN	1.27e-04	161	71	4	47b3b7662cbb671ccc086dc0a0cabd65f63eb5a1
ToppCell	COVID-19-kidney-Technical/muscle_(Imm)\|kidney / Disease (COVID-19 only), tissue and cell type	NRXN1 CNTN5 SAMD3 DMD	1.34e-04	163	71	4	19c28ce16a588a7f4a035c32726f6ccd67702b5b
ToppCell	LV-13._Vascular_Smooth_Muscle\|World / Chamber and Cluster_Paper	DGKH PAWR DMD UTRN	1.40e-04	165	71	4	f37fd95adc95d7753cf6e55ae819976513c7ec77
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c03-GZMK\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	HTR7 SYNE1 CYP21A2 SAMD3	1.47e-04	167	71	4	abc4ba308ca3be41b0da604f5d82579fd58dff7b
ToppCell	PND03-Endothelial-Endothelial_blood-vessel-Microvascular_EC-CAP2-CAP2_prolif\|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	NRXN1 PACC1 PAWR CAPN5	1.50e-04	168	71	4	c7021748003e5949f7caf7b3291c5bad294948c1
ToppCell	COVID-19-Heart-CM_+_Macrophage\|COVID-19 / Disease (COVID-19 only), tissue and cell type	PDE4DIP ACTN2 DMD MYBPC3	1.57e-04	170	71	4	3f15242a1d3e4e9871d9170b2ef05842fb609c29
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-glomerular_mesenchymal_cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	SYNE1 CNTN5 SSMEM1 SAMD3	1.64e-04	172	71	4	08a3fe536b1b064c5ee7779bc2b1115a5963a26b
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	SYNE1 CNTN5 SSMEM1 SAMD3	1.64e-04	172	71	4	553701349444eb366df3c11f54bb093434f153c6
ToppCell	Somatosensory_Cortex_(S1)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_D_(IT_RORB_THEMIS_LINC00507)_2-Exc_L3-4_RORB_PRSS12\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	CNTN5 DGKH SAMD3 UTRN	1.72e-04	174	71	4	ae363ce736fc8af439f3ad594d7bc2e344db80d4
ToppCell	kidney_cells-Hypertensive_with+without-CKD-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell-mesangial_typical-aged\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	NUGGC SYNE1 CNGA1 VCL	1.75e-04	175	71	4	1b4cefae400bf756d09ece32d3f5c0bd4c6ad73f
ToppCell	PBMC-Severe-Lymphocyte-T/NK-NK_cell-NK_CD56bright\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	SPAG1 DST PAWR SAMD3	1.75e-04	175	71	4	e219b61d6bc078d44ea7d06191d3462654d857a1
ToppCell	PBMC-Severe-Lymphocyte-T/NK-NK_cell-NK_CD56bright-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	SPAG1 DST PAWR SAMD3	1.75e-04	175	71	4	bd16c80418bf71127e6f1e50edf83967c9218b42
ToppCell	systemic_lupus_erythematosus-flare-Myeloid-conventional_dendritic_cell-male\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	DST HTR7 PACC1 SLC12A7	1.75e-04	175	71	4	c58a1f02d1e559d3638fe1500e960e82a8a7187b
ToppCell	COVID-19-Heart-CM_3\|COVID-19 / Disease (COVID-19 only), tissue and cell type	PDE4DIP ACTN2 DMD MYBPC3	1.79e-04	176	71	4	9df7a124ebafb0087da0cda133a394275d7bed81
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	SYNE1 CNTN5 PHYHIPL UTRN	1.79e-04	176	71	4	327a3e81b724252e36d786de92a3ffd721ea6d7b
ToppCell	Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L5-6_SST_ISOC1\|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	PAWR SAMD3 UTRN CNGA1	1.79e-04	176	71	4	d09e28606e2a6ed1f660898316765ca215085c18
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Descending_Thin_Limb_Cell_Type_1\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	SYNE1 CNTN5 PHYHIPL UTRN	1.83e-04	177	71	4	da8802a6351d3e510822f82e2fde8a4314a2216e
ToppCell	nucseq-Epithelial-Epithelial_Airway-Basal/Suprabasal\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	SERPINB3 SERPINB4 DGKH ECE1	1.83e-04	177	71	4	cbad1a23851151dbef01ea2af960e6f0944f838b
ToppCell	TCGA-Brain-Primary_Tumor-Low_Grade_Glioma\|TCGA-Brain / Sample_Type by Project: Shred V9	DST SYNE1 SPTAN1 PHYHIPL	1.83e-04	177	71	4	e8ab340b20cd41554c3841fe980e078e878af35f
ToppCell	10x5'v1-week_14-16-Myeloid_macrophage-stroma-osteoclast\|week_14-16 / cell types per 3 fetal stages;per 3',per 5'	SPATA12 PDE4DIP ACTN2 AHNAK2	1.87e-04	178	71	4	a28683690ab8a60eb18f3ef87ea85da4e95b22df
ToppCell	PBMC-Severe-cDC_11\|Severe / Compartment, Disease Groups and Clusters	PDE4DIP PAWR DMD ECE1	1.87e-04	178	71	4	0667abc05eb2254710b9c648c65b7cfdfe7831b7
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22-Lymphocytic-Lymphocytic_B-B_cell-B_c02-MS4A1-CD27\|Severe-critical_progression_d12-22 / Compartment, severity and other cell annotations on 10x 3' data (130k)	PIKFYVE IGSF22 ERCC4 PAWR	1.91e-04	179	71	4	a28a1de500a74c6dcc43481abf9ec0f7e7a300a9
ToppCell	Adult-Immune-T_lymphocyte-D122\|Adult / Lineage, Cell type, age group and donor	PCNX2 NUGGC SAMD3 FKBP5	1.95e-04	180	71	4	06c371d0f0c5a7b234dd143e98800e19af95a8b5
ToppCell	COVID-19-Heart-CM_+_EC_+_Pericyte\|COVID-19 / Disease (COVID-19 only), tissue and cell type	PDE4DIP ACTN2 DMD MYBPC3	1.99e-04	181	71	4	719eb532453ab7cd7893726885bc75d74a10b21e
ToppCell	COPD-Epithelial-Basal\|World / Disease state, Lineage and Cell class	SERPINB3 SERPINB4 DGKH PAWR	1.99e-04	181	71	4	6d8a886b4afe729f8a05b9c0f4ea9375de735da4
ToppCell	facs-Spleen-nan-3m-Lymphocytic-Cd3e_T_cell\|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ACTN2 SLC12A7 UTRN CNGA1	1.99e-04	181	71	4	be7c7db6b99603759593e6f79cdcaa4bbf234cb7
ToppCell	COVID-19-Heart-CM_3\|Heart / Disease (COVID-19 only), tissue and cell type	PDE4DIP ACTN2 DMD MYBPC3	2.04e-04	182	71	4	287fcc3897ae08841f6f85ae6c9cef16f75b1dd1
ToppCell	droplet-Heart-4Chambers-18m-Endothelial-endocardial_cell\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MAGEB3 PAWR ECE1 SLC12A7	2.08e-04	183	71	4	6c4a09c02e30e1f24dde39f8cb8c5b453826ee2e
ToppCell	COPD-Epithelial-Basal\|COPD / Disease state, Lineage and Cell class	SERPINB3 SERPINB4 DGKH PAWR	2.08e-04	183	71	4	0f760e393edc91009bf6c7e02eeac039a1dfb4ed
ToppCell	PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c01-LEF1\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	ABCC1 HTR7 DGKH SFI1	2.12e-04	184	71	4	bd786db4dc4edae6d5cfc0b69901983dea19f729
ToppCell	COVID-19-Heart-CM_2\|COVID-19 / Disease (COVID-19 only), tissue and cell type	PDE4DIP ACTN2 DMD MYBPC3	2.17e-04	185	71	4	549eeb521c3985bff396ea0f202db21822efa51f
ToppCell	10x3'2.3-week_14-16-Myeloid_macrophage-stroma-osteoclast\|week_14-16 / cell types per 3 fetal stages;per 3',per 5'	SPATA12 PDE4DIP ACTN2 AHNAK2	2.17e-04	185	71	4	5ed49b6d8214c6119355a6d3ee4e25d40bcc0c53
ToppCell	facs-Marrow-T-cells-3m-Lymphocytic-BM_CD8_+_CD4_T_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ACTN2 SAMD3 SLC12A7 UTRN	2.21e-04	186	71	4	4dce1484653bb266e2305cbb306fb11eaf7892e2
ToppCell	facs-Marrow-T-cells-3m-Lymphocytic-mature_alpha-beta_T_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ACTN2 SAMD3 SLC12A7 UTRN	2.21e-04	186	71	4	e23e1246914e230369a716d0d666b98383bf8512
ToppCell	droplet-Spleen-nan-3m-Lymphocytic-T_cell\|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ACTN2 SLC12A7 UTRN CNGA1	2.26e-04	187	71	4	1387981d224cb9e846ed18e366736855a4eb827e
ToppCell	facs-Lung-3m-Endothelial-arterial_endothelial-pulmonary_artery_endothelial_cell-pulmonary_artery_endothelial_cell_l25\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	DST ECE1 SLC12A7 UTRN	2.26e-04	187	71	4	7170694a1b86fe8d84d96c880ffe57af09bdc026
ToppCell	LA-03._Atrial_Cardiomyocyte\|World / Chamber and Cluster_Paper	PDE4DIP ACTN2 DMD MYBPC3	2.31e-04	188	71	4	6d249fe92d51a19da19ec14bb2262d394255d577
ToppCell	COVID-NK-\|COVID / Condition, Cell_class and T cell subcluster	SYNE1 PAWR SAMD3 UTRN	2.31e-04	188	71	4	fabdd68a9734d35e75e1f4a4bfd5c531cfc099f1
ToppCell	10x5'v1-week_17-19-Myeloid_macrophage-stroma-osteoclast\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	SPATA12 PDE4DIP ACTN2 AHNAK2	2.31e-04	188	71	4	762b52f21d2bc5409f86746a904c4358490be9c0
ToppCell	P28-Endothelial-large_vessel_endothelial_cell\|P28 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	DST ECE1 SLC12A7 UTRN	2.31e-04	188	71	4	263169029293e005bcffd87db20221fdd2d3917e
ToppCell	Healthy_donor-NK_CD56bright\|World / disease group, cell group and cell class (v2)	SPAG1 SYNE1 SFI1 SAMD3	2.31e-04	188	71	4	8ee359199c61c3b5b498ac35148390db5cc1a836
ToppCell	COVID-NK\|COVID / Condition, Cell_class and T cell subcluster	SYNE1 PAWR SAMD3 UTRN	2.31e-04	188	71	4	0beaa671611110a11e46156f54f5202cc24967a4
ToppCell	Children_(3_yrs)-Immune-T_lymphocyte-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	PCNX2 ABCC1 SFI1 FKBP5	2.35e-04	189	71	4	df30478b288084a1bd48f660409dcc784040897c
ToppCell	wk_15-18-Epithelial-PNS-PCP4+_neuron\|wk_15-18 / Celltypes from embryonic and fetal-stage human lung	NRXN1 HTR7 CNTN5 PHYHIPL	2.35e-04	189	71	4	22c927d2691b867fbdee1fbee042a6d3f7eadd7d
ToppCell	RV-06._Ventricular_Cardiomyocyte_II\|World / Chamber and Cluster_Paper	PDE4DIP ACTN2 DMD MYBPC3	2.35e-04	189	71	4	5e80c47f63980904c4c1ff02c201b67b456a0974
ToppCell	RV-15._Ventricular_Cardiomyocyte_III\|World / Chamber and Cluster_Paper	PDE4DIP ACTN2 DMD MYBPC3	2.35e-04	189	71	4	0a82931b5f6c0a6427ca3edd5e2235ac49099d40
ToppCell	COPD-Myeloid-ncMonocyte\|Myeloid / Disease state, Lineage and Cell class	ECE1 UTRN FKBP5 VCL	2.40e-04	190	71	4	ed978cd5d9da87b49878a330e362762c487f849f
ToppCell	BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c03-ITGA4\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	SPTAN1 METTL8 UTRN FKBP5	2.40e-04	190	71	4	91ba66d4b56c59523485b17738e93f14bb00afa4
ToppCell	RV-15._Ventricular_Cardiomyocyte_III\|RV / Chamber and Cluster_Paper	PDE4DIP ACTN2 DMD MYBPC3	2.40e-04	190	71	4	93c3188dfeb0b2f9889f8ae9b9c1f2f34129c99b
ToppCell	LV-06._Ventricular_Cardiomyocyte_II\|World / Chamber and Cluster_Paper	PDE4DIP ACTN2 DMD MYBPC3	2.40e-04	190	71	4	de5ef606a002f85c2e0e3a36c1f259d0b85a76ff
ToppCell	kidney_cells-Renal_AKI_(acute_kidney_injury)-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	SYNE1 CNTN5 PHYHIPL UTRN	2.40e-04	190	71	4	b855b8b7d3439023390ca44629c1a99f5d4c6801
ToppCell	Control-Endothelial-VE_Capillary_B\|Endothelial / Disease state, Lineage and Cell class	PITPNM2 SYNE1 DGKH FKBP5	2.40e-04	190	71	4	7f3f419fffe02934b6f27b697f7a6401072491ed
ToppCell	pdx-Tumor_cells-T8\|Tumor_cells / Sample and Cell Type and Tumor Cluster (all cells)	NUGGC DST ECE1 NAALADL2	2.40e-04	190	71	4	b05db0de9b6ae01dd30074453f7de44f7397631e
ToppCell	droplet-Heart-4Chambers-18m-Endothelial-endocardial_endothelial_cells\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MAGEB3 PAWR ECE1 SLC12A7	2.40e-04	190	71	4	6f71a9f74af7cd9a674753cfc9833ebe5bba0fa2
ToppCell	renal_medulla_nuclei-Adult_normal_reference\|renal_medulla_nuclei / Celltypes from Cells and Nuclei per compartment and clinical group	PITPNM2 PDE4DIP UTRN FKBP5	2.40e-04	190	71	4	f1363f7806cfc4f14fbc1b0e8dac2de813a88eee
ToppCell	kidney_cells-Renal_AKI_(acute_kidney_injury)-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Descending_Thin_Limb_Cell_Type_1\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	SYNE1 CNTN5 PHYHIPL UTRN	2.40e-04	190	71	4	a5db902ad112a0c0a0a7f1a2e38718bb3bd11412
ToppCell	droplet-Limb_Muscle-MUSCLE-30m-Mesenchymal-smooth_muscle_cell\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	HTR7 PAWR DMD VCL	2.40e-04	190	71	4	1ab3f19f1ce9f58e5125135704d94655a2e330a0
ToppCell	PBMC-Control-Lymphocyte-T/NK-NK_cell-NK_CD56bright\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	SPAG1 SYNE1 PAWR SAMD3	2.45e-04	191	71	4	f1935e8f8467a2bc30588b7f2cc3b94e9c83b268
ToppCell	PBMC-Control-Lymphocyte-T/NK-NK_cell-NK_CD56bright-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	SPAG1 SYNE1 PAWR SAMD3	2.45e-04	191	71	4	1161e465c50c2071764279e01cf08b1048cce0e3
ToppCell	LA-03._Atrial_Cardiomyocyte\|LA / Chamber and Cluster_Paper	PDE4DIP ACTN2 DMD MYBPC3	2.45e-04	191	71	4	5d1b674eb7703830b7ce8bbeac3363cabd0e6ae9
ToppCell	facs-Lung-3m-Endothelial-arterial_endothelial\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	DST ECE1 SLC12A7 UTRN	2.45e-04	191	71	4	6e6b2cb390cc5cd0356924a2c36fbe5b5bd5966c
ToppCell	PBMC-Control-Lymphocyte-T/NK-NK_cell-NK_CD56bright-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	SPAG1 SYNE1 PAWR SAMD3	2.45e-04	191	71	4	7a4fe96989f72159385270c712342ba3e1ca6fc3
ToppCell	facs-Lung-3m-Endothelial-arterial_endothelial-pulmonary_artery_endothelial_cell\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	DST ECE1 SLC12A7 UTRN	2.45e-04	191	71	4	482db995930346be69072ace2fd78fd453e97fb5
ToppCell	Basal_cells-IPF_02\|World / lung cells shred on cell class, cell subclass, sample id	SERPINB3 SERPINB4 ECE1 AHNAK2	2.45e-04	191	71	4	a98915bad9a4a61dd4cbca798914849b805f4a19
ToppCell	PBMC-Control-Lymphocyte-T/NK-NK_cell-NK_CD56bright\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	SPAG1 SYNE1 PAWR SAMD3	2.45e-04	191	71	4	c023ca893ceae19b54967096f6e2588dc39fa268
ToppCell	PBMC_fresh-frozen-Mild-Moderate_convalescent_d36-51-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c09-GZMK-FOS_l\|Mild-Moderate_convalescent_d36-51 / Compartment, severity and other cell annotations on 10x 3' data (130k)	NUGGC SYNE1 SPTAN1 SAMD3	2.45e-04	191	71	4	4a29b7d5cd10e9077699d3aa76e3db6c4d5a0cf6
ToppCell	IPF-Epithelial-Ciliated\|Epithelial / Disease state, Lineage and Cell class	SERPINI2 KIAA0825 SYNE1 DMD	2.55e-04	193	71	4	ad58f5080e0ba65c845056ea6b79037b636e9c64
ToppCell	severe-low-quality_cells\|severe / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	SYNE1 DGKH SFI1 UTRN	2.55e-04	193	71	4	9337bc93e3904c7fc7c93c328518bcd6453b1e8c
ToppCell	Influenza_Severe-CD8+_Tem\|World / Disease group and Cell class	NUGGC SYNE1 SAMD3 FKBP5	2.55e-04	193	71	4	fce6138712353fba14eb046e10d54e112372658e
ToppCell	10x_3'_v2v3-Non-neoplastic-Lymphoid-CD4/CD8-CD8_NK_sig-C\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	SYNE1 SAMD3 VCL AHNAK2	2.60e-04	194	71	4	6be74e4ba631b0c46cef2c580553f4c1ed29579e
Drug	Betahistine mesylate [54856-23-4]; Down 200; 17.2uM; PC3; HT_HG-U133A	ABCC1 NCOR2 ERCC4 SPTAN1 PDE4DIP GMEB1 CAPN5 ARAP1	1.63e-07	197	70	8	6611_DN
Drug	biopterin	SERPINB3 SERPINB4 CYP21A2 CNTN5 DMD	5.40e-06	82	70	5	CID000002380
Drug	plakin	DST SYNE1 SPTAN1 DMD UTRN	5.40e-06	82	70	5	CID000018752
Drug	thiirane	SERPINB3 SERPINB4 SYNE1	1.83e-05	17	70	3	CID000009865
Drug	Dantrolene sodium salt [14663-23-1]; Down 200; 11.8uM; PC3; HT_HG-U133A	NCOR2 ECE1 YY1 UTRN FKBP5 VCL	2.87e-05	193	70	6	4343_DN
Drug	rotenone; Up 200; 1uM; MCF7; HT_HG-U133A	SERPINI2 SPTAN1 PDE4DIP PACC1 FKBP5 AHNAK2	3.04e-05	195	70	6	5943_UP
Drug	Azathymine, 6 [932-53-6]; Up 200; 31.4uM; MCF7; HT_HG-U133A	NCOR2 CNTN5 PACC1 ACTN2 ARAP1 AHNAK2	3.13e-05	196	70	6	4106_UP
Drug	Racecadotril [81110-73-8]; Up 200; 10.4uM; MCF7; HT_HG-U133A	ABCC1 NCOR2 SFI1 CAPN5 TRIM38 ARAP1	3.13e-05	196	70	6	2774_UP
Drug	Etomidate [33125-97-2]; Up 200; 16.4uM; HL60; HT_HG-U133A	SYNE1 SPTAN1 PDE4DIP PACC1 YY1 ADA2	3.13e-05	196	70	6	2958_UP
Drug	Tetramisole hydrochloride [16595-80-5]; Down 200; 16.6uM; MCF7; HT_HG-U133A	PCNX2 ERCC4 ALMS1 CEP135 YY1 ARAP1	3.22e-05	197	70	6	2849_DN
Drug	Ketotifen fumarate [34580-14-8]; Up 200; 9.4uM; MCF7; HT_HG-U133A	ERCC4 ALMS1 DDX52 SPTAN1 PDE4DIP ECE1	3.22e-05	197	70	6	7199_UP
Drug	TCNB	ACTN2 DMD UTRN VCL MYBPC3	3.31e-05	119	70	5	CID000008330
Drug	Pronethalol hydrochloride [51-02-5]; Up 200; 15uM; MCF7; HT_HG-U133A	DDX52 SYNE1 SFI1 ECE1 TRIM38 AHNAK2	3.31e-05	198	70	6	4104_UP
Drug	Phenformin hydrochloride [834-28-6]; Up 200; 16.6uM; PC3; HT_HG-U133A	NCOR2 SERPINI2 HTR7 PDE4DIP SFI1 RNF17	3.31e-05	198	70	6	3725_UP
Drug	Sulfanilamide [63-74-1]; Down 200; 23.2uM; MCF7; HT_HG-U133A	PCNX2 ERCC4 DDX52 PDE4DIP PAWR UTRN	3.40e-05	199	70	6	6810_DN
Drug	THIP Hydrochloride; Up 200; 22.6uM; MCF7; HT_HG-U133A	PCNX2 ERCC4 SFI1 UTRN TRIM38 AHNAK2	3.40e-05	199	70	6	6511_UP
Drug	Oxethazaine [126-27-2]; Down 200; 8.6uM; MCF7; HT_HG-U133A	DDX52 PDE4DIP GMEB1 SFI1 UTRN ARAP1	3.40e-05	199	70	6	1484_DN
Drug	p181	SYNE1 ECE1	5.57e-05	4	70	2	CID000012208
Drug	IDETA	DMD UTRN	5.57e-05	4	70	2	CID003036201
Drug	Methamphetamine	NCOR2 MAGEB3 DST DDX52 SYNE1 SPTAN1 PDE4DIP DGKH PAWR METTL8 SFI1 DMD UTRN MYBPC3	7.82e-05	1401	70	14	ctd:D008694
Drug	dihydroquinoline 31	SERPINB3 SERPINB4	9.26e-05	5	70	2	CID010561174
Drug	ChAG	SERPINB3 SERPINB4	9.26e-05	5	70	2	CID000126253
Drug	NSC98537	PIKFYVE NCOR2 SERPINB3 SERPINB4 DDX52 CYP21A2 PAWR FKBP5	9.99e-05	473	70	8	CID000005410
Drug	m1 C	SERPINB3 SERPINB4 SYNE1	1.29e-04	32	70	3	CID000448219
Drug	diaziridine	SERPINB3 SERPINB4	1.39e-04	6	70	2	CID005059686
Drug	EDKC	SERPINB3 SERPINB4	1.39e-04	6	70	2	CID000129421
Drug	tiapamil	SYNE1 DMD	1.39e-04	6	70	2	CID000042106
Drug	DAU 6215	HTR7 SYNE1	1.39e-04	6	70	2	CID000060761
Drug	compound 20	SERPINB3 SERPINB4 ECE1	1.56e-04	34	70	3	CID000448214
Drug	Hy 1	SERPINB3 SERPINB4 CYP21A2	1.70e-04	35	70	3	CID000535161
Drug	azetidine	SERPINB3 SERPINB4 YY1	1.85e-04	36	70	3	CID000010422
Drug	AC1L1IOA	SERPINB3 SERPINB4	1.94e-04	7	70	2	CID000004663
Drug	ethylpiperazine	SERPINI2 SYNE1	1.94e-04	7	70	2	CID000079196
Drug	Calcort	CNTN5 DMD UTRN	2.17e-04	38	70	3	CID000026709
Drug	Perhexiline maleate [6724-53-4]; Up 200; 10.2uM; HL60; HT_HG-U133A	PCNX2 SYNE1 PDE4DIP PACC1 MYBPC3	2.33e-04	180	70	5	2410_UP
Drug	Trichostatin A, from Streptomyces sp.; Up 200; 0.1uM; PC3; HT_HG-U133A	PDE4DIP RNF17 CNGA1 TRIM38 AHNAK2	2.33e-04	180	70	5	4344_UP
Drug	3'-deoxy-ara-C	SERPINB3 SERPINB4	2.58e-04	8	70	2	CID000122111
Drug	norcyclizine	SERPINI2 SYNE1	2.58e-04	8	70	2	CID000070048
Drug	AC1L1DW2	PIKFYVE SPAG1 YY1 UTRN VCL	2.71e-04	186	70	5	CID000002532
Drug	Amitryptiline hydrochloride [549-18-8]; Down 200; 12.8uM; HL60; HT_HG-U133A	PRPF31 SPAG1 ALMS1 SPTAN1 ARAP1	2.85e-04	188	70	5	1865_DN
Drug	wortmannin from Penicillium funiculosum; Down 200; 0.01uM; MCF7; HT_HG-U133A_EA	SPAG1 ERCC4 ALMS1 UTP20 FKBP5	3.07e-04	191	70	5	1023_DN
Drug	Hexetidine [141-94-6]; Down 200; 11.8uM; MCF7; HT_HG-U133A	ERCC4 SFI1 ECE1 UTRN AHNAK2	3.14e-04	192	70	5	3318_DN
Drug	Carbenoxolone disodium salt [7421-40-1]; Down 200; 6.6uM; MCF7; HT_HG-U133A	ERCC4 ALMS1 PDE4DIP ECE1 UTRN	3.22e-04	193	70	5	4173_DN
Drug	Methocarbamol [532-03-6]; Down 200; 16.6uM; PC3; HT_HG-U133A	SPTAN1 PDE4DIP CAPN5 UTRN TRIM38	3.30e-04	194	70	5	2111_DN
Drug	LS-83913	SERPINB3 SERPINB4	3.31e-04	9	70	2	CID005488161
Drug	methylarsine	ABCC1 FKBP5	3.31e-04	9	70	2	ctd:C543395
Drug	Beclomethasone dipropionate [5534-09-8]; Up 200; 7.6uM; HL60; HT_HG-U133A	NCOR2 CAPN5 SLC12A7 FKBP5 ARAP1	3.37e-04	195	70	5	3001_UP
Drug	(d,l)-Tetrahydroberberine [522-97-4]; Down 200; 11.8uM; HL60; HT_HG-U133A	ABCC1 SLC12A7 YY1 FKBP5 ARAP1	3.37e-04	195	70	5	2163_DN
Drug	Glycocholic acid [475-31-0]; Down 200; 8.6uM; MCF7; HT_HG-U133A	PAWR ECE1 UTRN FKBP5 ARAP1	3.37e-04	195	70	5	3315_DN
Drug	Flurbiprofen [5104-49-4]; Down 200; 16.4uM; MCF7; HT_HG-U133A	ALMS1 PDE4DIP CEP135 PAWR ECE1	3.37e-04	195	70	5	5269_DN
Drug	Papaverine hydrochloride [61-25-6]; Up 200; 10.6uM; MCF7; HT_HG-U133A	SPTAN1 PDE4DIP GMEB1 SFI1 ARAP1	3.37e-04	195	70	5	6245_UP
Drug	Ofloxacin [82419-36-1]; Up 200; 11uM; PC3; HT_HG-U133A	PCNX2 NCOR2 SPTAN1 ECE1 YY1	3.37e-04	195	70	5	7372_UP
Drug	Myricetin [529-44-2]; Down 200; 12.6uM; MCF7; HT_HG-U133A	PDE4DIP SFI1 UTRN ARAP1 AHNAK2	3.37e-04	195	70	5	4170_DN
Drug	Oxamniquine [21738-42-1]; Up 200; 14.4uM; MCF7; HT_HG-U133A	NCOR2 CEP135 SFI1 ARAP1 AHNAK2	3.37e-04	195	70	5	4124_UP
Drug	Netilmicin sulfate [56931-57-2]; Down 200; 2.8uM; MCF7; HT_HG-U133A	ERCC4 SPTAN1 PDE4DIP YY1 FKBP5	3.45e-04	196	70	5	3524_DN
Drug	Fillalbin [4540-25-4]; Down 200; 13.8uM; MCF7; HT_HG-U133A	ERCC4 PDE4DIP GMEB1 PAWR SFI1	3.45e-04	196	70	5	4172_DN
Drug	0179445-0000 [211246-22-9]; Down 200; 1uM; MCF7; HT_HG-U133A	PAWR SFI1 ECE1 YY1 AHNAK2	3.45e-04	196	70	5	3633_DN
Drug	Phenylpropanolamine hydrochloride [154-41-6]; Up 200; 21.4uM; MCF7; HT_HG-U133A	PDE4DIP PAWR UTRN FKBP5 AHNAK2	3.45e-04	196	70	5	5298_UP
Drug	Hydralazine hydrochloride [304-20-1]; Down 200; 20.4uM; PC3; HT_HG-U133A	PCNX2 NCOR2 SPTAN1 ECE1 YY1	3.45e-04	196	70	5	3724_DN
Drug	Sulfadoxine [2447-57-6]; Up 200; 12.8uM; PC3; HT_HG-U133A	PDE4DIP SFI1 ACTN2 YY1 ARAP1	3.45e-04	196	70	5	5852_UP
Drug	Lidocaone hydrochloride [73-78-9]; Up 200; 14.8uM; PC3; HT_HG-U133A	CEP135 SFI1 ECE1 CNGA1 ARAP1	3.45e-04	196	70	5	4596_UP
Drug	aspirin, USP; Down 200; 100uM; MCF7; HT_HG-U133A	PRPF31 DDX52 PDE4DIP CEP135 YY1	3.45e-04	196	70	5	6924_DN
Drug	Diethylstilbestrol [56-53-1]; Up 200; 15uM; PC3; HT_HG-U133A	ERCC4 CEP135 PACC1 ACTN2 CNGA1	3.45e-04	196	70	5	4547_UP
Drug	Iopamidol [60166-93-0]; Up 200; 5.2uM; MCF7; HT_HG-U133A	ERCC4 ALMS1 SPTAN1 PAWR ECE1	3.45e-04	196	70	5	3473_UP
Drug	(-)-Adenosine 3',5'-cyclic monophosphate [60-92-4]; Up 200; 12.2uM; HL60; HT_HG-U133A	PCNX2 SPTAN1 ADA2 FKBP5 ARAP1	3.45e-04	196	70	5	2969_UP
Drug	genistein; Up 200; 10uM; MCF7; HT_HG-U133A	SPTAN1 PDE4DIP SFI1 CAPN5 ARAP1	3.45e-04	196	70	5	5232_UP
Drug	Cefoperazone dihydrate; Down 200; 5.8uM; PC3; HT_HG-U133A	NCOR2 SPTAN1 PDE4DIP GMEB1 YY1	3.45e-04	196	70	5	6323_DN
Drug	Diphenylpyraline hydrochloride [132-18-3]; Up 200; 12.6uM; MCF7; HT_HG-U133A	SFI1 ACTN2 ECE1 CCDC70 ARAP1	3.45e-04	196	70	5	6061_UP
Drug	Alclometasone dipropionate [667634-13-2]; Up 200; 7.6uM; MCF7; HT_HG-U133A	SPTAN1 PDE4DIP SFI1 YY1 ARAP1	3.45e-04	196	70	5	6229_UP
Drug	arachidonic acid sodium salt; Down 200; 10uM; MCF7; HG-U133A	SERPINI2 ALMS1 GMEB1 YY1 TRIM38	3.54e-04	197	70	5	441_DN
Drug	Monensin sodium salt [22373-78-0]; Down 200; 5.8uM; PC3; HT_HG-U133A	NCOR2 ERCC4 SERPINI2 PAWR RNF17	3.54e-04	197	70	5	3704_DN
Drug	Alfaxalone [23930-19-0]; Up 200; 12uM; MCF7; HT_HG-U133A	NCOR2 PACC1 ACTN2 UTRN ARAP1	3.54e-04	197	70	5	6514_UP
Drug	Pramoxine hydrochloride [637-58-1]; Up 200; 12.2uM; MCF7; HT_HG-U133A	SERPINI2 PDE4DIP SFI1 ECE1 TRIM38	3.54e-04	197	70	5	6054_UP
Drug	PHA-00745360 [351320-33-7]; Up 200; 10uM; PC3; HT_HG-U133A	HTR7 DDX52 PACC1 RNF17 FKBP5	3.54e-04	197	70	5	4559_UP
Drug	Cyanocobalamin [68-19-9]; Up 200; 3uM; PC3; HT_HG-U133A	NCOR2 ERCC4 SERPINI2 FKBP5 VCL	3.54e-04	197	70	5	4572_UP
Drug	Piromidic acid [19562-30-2]; Down 200; 13.8uM; PC3; HT_HG-U133A	DDX52 SPTAN1 PDE4DIP ECE1 UTRN	3.54e-04	197	70	5	4575_DN
Drug	Pridinol methanesulfonate salt [6856-31-1]; Up 200; 10.2uM; PC3; HT_HG-U133A	MAGEB3 ERCC4 PDE4DIP SFI1 ACTN2	3.54e-04	197	70	5	5860_UP
Drug	Crotamiton [483-63-6]; Up 200; 19.6uM; MCF7; HT_HG-U133A	PCNX2 PACC1 ECE1 TRIM38 ARAP1	3.54e-04	197	70	5	3388_UP
Drug	Lisinopril [83915-83-7]; Down 200; 9uM; HL60; HT_HG-U133A	SPTAN1 GMEB1 CAPN5 ADA2 UTRN	3.54e-04	197	70	5	2371_DN
Drug	3H-diazirine	DST SERPINB3 SERPINB4	3.60e-04	45	70	3	CID000078958
Drug	Dropropizine (R,S) [17692-31-8]; Down 200; 17uM; MCF7; HT_HG-U133A	PCNX2 ABCC1 GMEB1 CAPN5 ARAP1	3.62e-04	198	70	5	5531_DN
Drug	LY 294002; Up 200; 0.1uM; MCF7; HT_HG-U133A	ABCC1 ALMS1 PDE4DIP SFI1 UTRN	3.62e-04	198	70	5	6976_UP
Drug	Doxycycline hydrochloride [10592-13-9]; Up 200; 8.4uM; MCF7; HT_HG-U133A	ERCC4 ECE1 UTRN ARAP1 AHNAK2	3.62e-04	198	70	5	3479_UP
Drug	Acetazolamide [59-66-5]; Up 200; 18uM; HL60; HT_HG-U133A	SYNE1 PDE4DIP SFI1 ACTN2 FKBP5	3.62e-04	198	70	5	1850_UP
Drug	Pindolol [13523-86-9]; Up 200; 16.2uM; PC3; HT_HG-U133A	SERPINI2 PDE4DIP CEP135 SFI1 ECE1	3.62e-04	198	70	5	4496_UP
Drug	Bemegride [64-65-3]; Down 200; 25.8uM; PC3; HT_HG-U133A	DDX52 SYNE1 PDE4DIP SFI1 CNGA1	3.62e-04	198	70	5	6668_DN
Drug	Niridazole [61-57-4]; Down 200; 18.6uM; PC3; HT_HG-U133A	SPTAN1 ECE1 YY1 UTRN ARAP1	3.62e-04	198	70	5	4621_DN
Drug	Gramine [87-52-5]; Down 200; 23uM; MCF7; HT_HG-U133A	ERCC4 ALMS1 PDE4DIP UTRN ARAP1	3.62e-04	198	70	5	2799_DN
Drug	Clofilium tosylate [92953-10-1]; Up 200; 7.8uM; PC3; HT_HG-U133A	NCOR2 ERCC4 SFI1 CNGA1 MYBPC3	3.62e-04	198	70	5	4492_UP
Drug	Chlorthalidone [77-36-1]; Up 200; 11.8uM; MCF7; HT_HG-U133A	DDX52 PDE4DIP CAPN5 YY1 UTRN	3.62e-04	198	70	5	6800_UP
Drug	Viomycin sulfate [37883-00-4]; Up 200; 5.2uM; HL60; HT_HG-U133A	PRPF31 PDE4DIP SFI1 SLC12A7 ADA2	3.62e-04	198	70	5	2979_UP
Drug	Pantothenic acid calcium salt monohydrate [63409-48-3]; Up 200; 8uM; MCF7; HT_HG-U133A	NCOR2 DDX52 ECE1 YY1 AHNAK2	3.62e-04	198	70	5	3248_UP
Drug	Dipyridamole [58-32-2]; Up 200; 8uM; MCF7; HT_HG-U133A	NCOR2 DMD RNF17 TRIM38 CCDC70	3.62e-04	198	70	5	5617_UP
Drug	H-89, Dihydrochloride; Down 200; 0.5uM; MCF7; HT_HG-U133A	HTR7 SPTAN1 GMEB1 SFI1 SLC12A7	3.62e-04	198	70	5	6878_DN
Drug	Sulconazole nitrate [61318-91-0]; Up 200; 8.6uM; PC3; HT_HG-U133A	NCOR2 HTR7 PDE4DIP CEP135 SFI1	3.62e-04	198	70	5	6652_UP
Drug	Pyridoxine hydrochloride [58-56-0]; Up 200; 19.4uM; MCF7; HT_HG-U133A	ERCC4 SPTAN1 PDE4DIP SFI1 FKBP5	3.70e-04	199	70	5	7171_UP
Drug	Estrone [53-16-7]; Down 200; 14.8uM; MCF7; HT_HG-U133A	PRPF31 ALMS1 HTR7 SPTAN1 SFI1	3.70e-04	199	70	5	6448_DN
Drug	Scopolamine hydrochloride [55-16-3]; Down 200; 11.8uM; MCF7; HT_HG-U133A	ERCC4 SPTAN1 PDE4DIP PAWR ECE1	3.70e-04	199	70	5	3357_DN
Drug	2-propylpentanoic acid; Down 200; 1000uM; HL60; HT_HG-U133A	SFI1 ACTN2 YY1 TRIM38 ARAP1	3.70e-04	199	70	5	6168_DN
Drug	Thyroxine (L) [51-48-9]; Up 200; 5.2uM; MCF7; HT_HG-U133A	ERCC4 DDX52 SFI1 YY1 UTRN	3.70e-04	199	70	5	3249_UP
Disease	Familial dilated cardiomyopathy	ACTN2 DMD VCL MYBPC3	3.46e-06	44	69	4	C0340427
Disease	Primary familial hypertrophic cardiomyopathy	ACTN2 VCL MYBPC3	1.83e-05	22	69	3	cv:C0949658
Disease	gamma-glutamylcitrulline measurement	ABCC1 CYP21A2	3.22e-05	4	69	2	EFO_0800690
Disease	Primary dilated cardiomyopathy	ACTN2 VCL MYBPC3	6.95e-05	34	69	3	cv:C0007193
Disease	Cardiomyopathy	ACTN2 VCL MYBPC3	1.84e-04	47	69	3	cv:C0878544
Disease	PITUITARY DWARFISM I	ERCC4 LARP7	1.92e-04	9	69	2	C0342573
Disease	Cardiomyopathies	ACTN2 DMD VCL MYBPC3	2.49e-04	130	69	4	C0878544
Disease	glutaroyl carnitine measurement	ABCC1 CYP21A2	4.13e-04	13	69	2	EFO_0021005
Disease	cleft lip	NCOR2 DST SYNE1 ZNF283 NAALADL2	5.42e-04	284	69	5	EFO_0003959
Disease	Proteinuria	SAMD3 RSL24D1	5.55e-04	15	69	2	HP_0000093
Disease	glutarylcarnitine (C5-DC) measurement	ABCC1 CYP21A2	7.16e-04	17	69	2	EFO_0800030
Disease	muscular dystrophy (implicated_via_orthology)	DMD UTRN	1.10e-03	21	69	2	DOID:9884 (implicated_via_orthology)
Disease	hypertrophic cardiomyopathy (is_implicated_in)	VCL MYBPC3	1.21e-03	22	69	2	DOID:11984 (is_implicated_in)
Disease	Autosomal Recessive Primary Microcephaly	CEP135 KIF14	1.21e-03	22	69	2	C3711387
Disease	retinal vasculature measurement	ERCC4 CYP21A2 CFDP1 PAWR CAPN5 SLC12A7	1.33e-03	517	69	6	EFO_0010554
Disease	Dwarfism	ERCC4 LARP7	1.56e-03	25	69	2	C0013336
Disease	migraine disorder, diastolic blood pressure	NCOR2 CFDP1	1.56e-03	25	69	2	EFO_0006336, MONDO_0005277
Disease	FEV change measurement, response to zileuton	NRXN1 CYP21A2	1.56e-03	25	69	2	EFO_0005921, EFO_0007676
Disease	caudate volume change measurement, age at assessment	NRXN1 CNTN5	1.82e-03	27	69	2	EFO_0008007, EFO_0021491
Disease	Primary familial dilated cardiomyopathy	ACTN2 VCL	2.25e-03	30	69	2	cv:C0340427

Protein segments in the cluster

Peptide	Gene	Start	Entry
IQWMSSVEAKIEDKK	DDX52	106	Q9Y2R4
TVTMDELRTKWDKVK	ACTN2	601	P35609
TSWSEEKREEKMLFT	ALMS1	3926	Q8TCU4
SFWEMEKSFREEEKT	CCDC70	106	Q6NSX1
EWQKVSKSEREKMGV	CAPN5	301	O15484
NDWLTKTEERTRKME	DMD	461	P11532
WKEKMVTSSEASKFI	CNTN5	821	O94779
TTDFLEEWKAKREKM	PAWR	16	Q96IZ0
TLKSFEKAKESWEMD	FKBP5	246	Q13451
ESSRWTEEEMETAKK	NCOR2	611	Q9Y618
EKWKTAEIDSVKMTL	KIF14	131	Q15058
AETSKMKVLEFWAKV	MAGEB3	281	O15480
SVLLKNRWEMKKDET	KIAA0825	1231	Q8IV33
KKDSEEISEDTLMFW	GMEB1	246	Q9Y692
SDWVSEKSKSVKDIE	DST	3526	Q03001
LNSKRTIEEAMVKKW	CYP21A2	71	P08686
KMKDSVTDVLKWDLI	PCNX2	1086	A6NKB5
SGKDDTQIIKRDEWM	CWF19L2	141	Q2TBE0
LRVLSKSEWMDLKKE	LARP7	376	Q4G0J3
KWVEVKSKRRDMTVF	NRXN1	136	Q9ULB1
KDITKWSSNDLMDKI	PITPNM2	361	Q9BZ72
ENRKEMEDWISSLKS	DGKH	141	Q86XP1
FRTWVKMSLVKTKEE	PACC1	236	Q9H813
EVSRWESLMAAKEKE	CEP135	861	Q66GS9
FTWDKKLEMVVKSTG	PIKFYVE	2041	Q9Y2I7
VWMDEKTRQAAKEKA	EEF1AKMT4-ECE2	596	P0DPD8
QKMSTLEKSKLDWES	CFDP1	236	Q9UEE9
LEMRAEDTKEWSKCT	IGSF22	836	Q8N9C0
WMEERRKFTRDTDKT	CFAP107	31	Q8N1D5
LESEKNTFMEIWKKR	ADA2	486	Q9NZK5
TLKWMDEETRKSAKE	ECE1	481	P42892
ELARDSEKKSDMEWT	HLTF	816	Q14527
EKASWSSLSMDEKVE	COX4I1	66	P13073
KVQMTWTREKLIAEK	SLC12A7	976	Q9Y666
MQWSKEEEAAARKKV	METTL8	51	Q9H825
MLEDKKRATDWEATN	OTUD5	381	Q96G74
FEKTVKIRMTFDTWK	PPP1R3B	156	Q86XI6
KEETWKLMEADKAQT	ABCC1	941	P33527
FKISWEMDSKSKDRI	PHYHIPL	66	Q96FC7
WKENTMARVDEAKKT	SFI1	691	A8K8P3
KISLEKKDWLFDMVT	UTP20	2356	O75691
MRKQSSEVKEKWESL	UTRN	2661	P46939
DFNSKRDEMWKKTID	NUGGC	296	Q68CJ6
RDEMWKKTIDKCSVI	NUGGC	301	Q68CJ6
EQKLSTAMRITKWKE	TRIM38	156	O00635
LVKTDMESTVDKWLD	SYNE1	2166	Q8NF91
MESTVDKWLDVSEKL	SYNE1	2171	Q8NF91
WKDEKDERMSQKVAF	NBPF7P	381	P0C2Y1
SRASVWMSEDKKDEG	SSMEM1	56	Q8WWF3
VKTEKDWREIDKRMS	SAMD3	296	Q8N6K7
IDTKSVTKDIWKEMN	PNLDC1	291	Q8NA58
SWKLAKMIEAREKEQ	SMIM15	41	Q7Z3B0
KLEEKLTAEKLMEWT	SERPINB3	256	P29508
NWLADKMLTTVEKKV	HTR7	461	P34969
DLASMEDKTEKWSSQ	AHNAK2	5336	Q8IVF2
KVRSLKMDRKVWTET	ARAP1	586	Q96P48
NVSKDMEKRVIKWFD	CNGA1	421	P29973
RTMQWSKEAKEKFEE	RNF17	801	Q9BXT8
TLEKSGDTWEMKALD	SPATA12	11	Q7Z6I5
KSWVNEKMKTATDEA	SPTAN1	586	Q13813
VTMWSSDEKKDIDHE	YY1	221	P25490
SWVSEIKKEEDKMHF	SPAG1	101	Q07617
DAWASKDTEAMKRAL	VCL	256	P18206
DSVKTIAKLWDSKMF	PRPF31	46	Q8WWY3
WNKTIDAMKRVEEIK	RSL24D1	86	Q9UHA3
KLEEKLTAEKLMEWT	SERPINB4	256	P48594
STWVERKTDGKIKDM	SERPINI2	151	O75830
IGWSSSEKKDELMNK	ZNF507	456	Q8TCN5
AEEVWMKFRKEDSSK	ERCC4	446	Q92889
SQWEMKDKSKTLGLE	ZNF283	136	Q8N7M2
EDDMEISKKIKTQWT	NAALADL2	191	Q58DX5
LKEEMETKFSRWQKE	PDE4DIP	561	Q5VU43
TVQKADKKTMEWFTV	MYBPC3	1101	Q14896